Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - An in situ hybridization study

Journal of Neuropathology and Experimental Neurology

Volumn 56, Issue 4, 1997, Pages 440-454

  Arzberger, Thomas ^a   Krampfl, Klaus ^a   Leimgruber, Susanne ^a   Weindl, Adolf ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Co localization; Excitotoxicity; Glial fibrillary acidic protein; Glutamate transporter 1; Huntington's disease; In situ hybridization; NDMA receptor subunits

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID TRANSFER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBUNIT;

ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL PROLIFERATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; HYPERKINESIA; IN SITU HYBRIDIZATION; MEMBRANE BINDING; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 0030708576     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199704000-00013     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83
2. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends Neurosci 1995;18:11-14
3. Martin JB, Gusella JF. Huntington's Disease - Pathogenesis and management. N Engl J Med 1986;315:1267-76
4. Forno LS, Jose C. Huntington's chorea: A pathological study. In: Barbeau A, Chase TN, Paulson GW, eds. Huntington's chorea. Advances in Neurology. Vol. I. New York: Raven Press, 1973:453-70
5. Kowall NW, Ferrante RJ, Martin JB. Patterns of cell loss in Huntington's disease. Trends Neurosci 1987;10:24-29
6. Reiner A, Albin RL, Anderson KD, D'Amato C, Penney JB, Young BY. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci 1988;85:5733-37
7. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Am Neurol 1992;31:425-30
8. Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol 1995;38:852-61
9. Bruyn GW. Huntington's chorea: Historical, clinical and laboratory synopsis. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. Vol. 6. Amsterdam: North Holland, 1968:379-96
10. Divac I, Fonnum F, Storm-Mathisen. High affinity uptake of glutamate in terminals of corticostriatal axons. Nature 1977;266:377-88
11. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244-54
12. Whetsell WO. Current concepts of excitotoxicity. J Neuropathol Exp Neurol 1996;55:1-13
13. Monyer H, Sprengel R, Schoepfer R, et al. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 1992;256:1217-21
14. Foldes RL, Rampersad V, Kamboj RK. Cloning and sequence analysis of additional splice variants encoding human N-methyl-D-aspartate receptor (hNR1) subunits. Gene 1994;147:303-4
15. Foldes RL, Adams SL, Fantaske RP, Kamboj RK. Human N-methyl-D-aspartate receptor modulatory subunit hNR2A: Cloning and sequencing of the cDNA and primary structure of the protein. Bba Mol Cell Res 1994;1223:155-59
16. Adams SL, Foldes RL, Kamboj RK. Human N-methyl-D-aspartate receptor modulatory subunit hNR3: Cloning and sequencing of the cDNA and primary structure of the protein. Bba Gene Struct Express 1995;1260:105-8
17. Shashidharan P, Plaitakis A. Cloning and characterization of a glutamate transporter cDNA from human cerebellum. Biochim Biophys Acta 1993;1216:161-64
18. Shashidharan P, Wittenberg I, Plaitakis A. Molecular cloning of human brain glutamate/aspartate transporter II. Bba Biomembranes 1994;1191:393-96
19. Shashidharan P, Huntley GW, Meyer T, Morrison JH, Plaitakis A. Neuron-specific human glutamate transporter: Molecular cloning, characterization and expression in human brain. Brain Res 1994; 662:245-50
20. Rothstein JD, Martin L, Levey AI, et al. Localization of neuronal and glial glutamate transporters. Neuron 1994;13:713-25
21. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC. Differential expression of two glial glutamate transporters in the rat brain: Quantitative and immunocytochemical observations. J Neurosci 1995;15:1835-53
22. Gerfen CR, Baimbridge KG, Miller JJ. The neostriastal mosaic: Compartmental distribution of calcium-binding protein and parval-bumin in the basal ganglia of the rat and monkey. Proc Natl Acad Sci USA 1985;82:8780-84
23. Bignami A, Eng LF, Dahl D, Uyeda CT. Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res 1972;43:429-35
24. Steinert PM. Intermediate filaments: Conformity and diversity of expression and structure. Ann Rev Cell Biol 1985;1:41-65
25. Vonsattel J-P, Myers R, Stevens TJ, Ferrante JR, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77
26. Wisden W, Morris BJ, Hunt SP, In situ hybridization with synthetic DNA probes. In: Chad J, Wheal H, eds. Molecular neurobiologya practical approach. Vol II. Oxford: IRL Press, 1991:205-25
27. Akbarian S, Sucher NJ, Bradley, D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30
28. Lange H, Thörner G, Hopf A, Schröder KF. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976;28:401-25
29. Dure IV LS, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 1991;30:785-93
30. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988;241:981-83
31. Williams K. Modulation of the N-methyl-D-aspartate receptor by polyamines: Molecular pharmacology and mechanisms of action. Biochem Soc Trans 1994;22:884-87
32. Illarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 1994;36:630-34
33. Furtado S, Suchowersky O, Rewcastle B, et al. Relationship between trinucleotide repeats and neuropathological changes. Ann Neurol 1996;39:132-36
34. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropath Exp Neurol 1995;54:105-20
35. Cross AJ, Slater P, Reynolds GP. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neurosci Lett 1986;67:198-202
36. Levy LM, Lehre KP, Walaas SI, Storm-Mathisen J, Danbolt NC. Down-regulation of glial glutamate transporters after glutamatergic denervation in the rat brain. Eur J Neurosci 1995;7:2036-41
37. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol 1994;4: 229-37
38. O'Callaghan JP. Assessment of neurotoxicity: Use of glial fibrillary acidic protein as a biomarker. Biomed Environment Sci 1991;4: 197-206
39. McLendon RE, Bigner DD. Immunohistochemistry of the glial fibrillary acidic protein: Basic and applied considerations. Brain Pathol 1994;4:221-28
40. Seto-Ohshima A, Emson PC, Lawson E, Mountjoy CQ, Carrasco LH. Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet 1988;i:1252-55